Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2021

View Archived Issues

Aston Sci studies AST-021p for advanced solid tumors in phase I

DIO2 is a regulator of mitochondrial activity in developing human cardiomyocytes

TruLarv standardized Galleria mellonella developed for screening new antimicrobials

New beta-amyloid PET imaging agent [18F]Flotaza shows promise in Alzheimer's disease brain

Positive interim data from phase Ib study of ARO-HIF2 in clear cell renal cell carcinoma

First patient dosed in phase IIb study of Lomecel-B in hypoplastic left heart syndrome

Positive phase I data for UBX-1325 in patients with advanced vascular eye disease

FDA clears IND for AGEN-1777

Vanderbilt University patents muscarinic M4 receptor antagonists

Shionogi discloses new HDAC2 inhibitors

Kymera Therapeutics patents new PROTACs

Eli Lilly and Company synthesizes GTPase KRAS mutant inhibitors

Ifenprodil will not advance into phase III trial for COVID-19

Intra-Cellular Therapies identifies new gamma-carboline derivatives

NMPA accepts IND application for TST-002 anti-sclerostin monoclonal antibody

SYNB-8802 significantly lowers urinary oxalate in NHP model of hyperoxaluria

Dapagliflozin similarly reduces risk of worsening in Black and White patients with HFrEF

Adamtsl3 knockout leads to dilated cardiomyopathy in aortic banded mice

APOBEC3B may be a therapeutic target for treating ovarian cancer

Studies report on developmental, adult neurogenesis

NextCure's NC-762 enters phase I/II trial in advanced or metastatic solid tumors

Opiant reports topline data from confirmatory PK study of OPNT-003 for opioid overdose

FDA clears initiation of phase II trials of YH-001 and YH-003 in advanced cancers

Sorrento cleared in U.S. to begin phase II study of resiniferatoxin in knee osteoarthritis pain

EpimAb Biotherapeutics commences dosing in phase I/II trials of EMB-06 and EMB-02

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...